Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 8th Preview)
-
Cell therapy approval path resets for Ebvallo
The FDA has agreed to reconsider approval for Atara Biotherapeutics and Pierre Fabre Pharmaceuticals’ allogeneic T-cell therapy Ebvallo (tabelecleucel) after a surprise January rejection. The companies said a late-April meeting led to a potential path where a single-arm study with an appropriate historical control could be “adequate and well controlled” for a BLA review. Ebvallo targets EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) in patients who have failed an anti-CD20 regimen. European regulators approved the therapy for the indication in 2022, but the U.S. review questioned whether the Allele single-arm trial could support regulatory standards. Atara and Pierre Fabre plan to resubmit without launching a new trial, instead adding patients and longer follow-up to the existing dataset. The approach, if accepted, could compress timelines for an ultra-rare, aggressive indication that currently has no FDA-approved options.
-
Big Pharma M&A: Angelini buys Catalyst to expand rare neuro portfolio in the U.S.
Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion in cash, adding three FDA-approved rare disease medicines to its portfolio and creating a direct entry into the U.S. market. The deal brings Catalyst’s marketed franchise into Angelini’s neurology strategy, with expected closing in the third quarter of 2026. Catalyst’s product lineup includes Firdapse for Lambert-Eaton myasthenic syndrome, Agamree for Duchenne muscular dystrophy, and Fycompa for certain seizure types. Catalyst reported 2025 revenue of about $589 million, a 19.8% increase over 2024, driven by growth in its rare neuromuscular assets. Angelini said the acquisition strengthens its global commercial infrastructure while supporting continued development of neurology-focused programs, including epilepsy candidates in active clinical trials.
-
Digital pathology consolidation: Roche to buy PathAI
Roche agreed to acquire PathAI for up to $1.05 billion to expand its digital pathology capabilities and bolster biopharma services. Under the terms, Roche will pay $750 million upfront and up to $300 million in milestone payments, with a target close in the second half of 2026 subject to approvals. Roche said the deal will give it access to PathAI’s Image Management System (IMS), software designed to connect image analysis with lab workflows. The company also plans to merge PathAI into its Diagnostics division and scale the platform globally. The acquisition follows a partnership that began in 2021 and expanded in 2024 around AI-enabled companion diagnostics. PathAI’s prior FDA milestone includes qualification of its AIM-NASH tool for evaluating fatty liver disease in clinical trials.
-
FDA reconsideration of T-cell therapy in EBV+ PTLD boosts Atara’s odds
The FDA’s updated stance on Ebvallo centers on using the existing single-arm Allele trial with an appropriate historical control rather than demanding a new randomized study. The companies said the agency’s position could allow a resubmission plan supported by additional patients and longer follow-up. The shift is especially relevant because Ebvallo targets an ultra-rare population with limited post-transplant options. Failure after anti-CD20 therapy leaves patients with EBV+ PTLD facing very short time-to-progression. Together with the European approval in 2022, the U.S. reconsideration represents the clearest route yet to an FDA decision based primarily on the already-completed study design.
-
Immuno-oncology pipeline stumbles: Entrada and Engene face sharp reversals on early bladder/DMD oncology data
Entrada’s shares plunged after initial dystrophin readouts for ENTR-601-44 in Duchenne muscular dystrophy came in below what investors expected. The trial met safety and tolerability, and researchers reported functional benefits including time-to-rise changes, but investors focused on dystrophin production relative to baseline. Meanwhile, Engene Therapeutics’ stock also suffered steep losses following additional interim data for detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The updates arrived ahead of further pivotal readouts, and the market response suggested that the incremental efficacy signals were not enough to offset concerns. These moves underline how early protein-expansion or disease-control metrics can quickly reshape valuation in mutation-specific oncology programs.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.